Volitionrx Limited Quick Ratio (VNRX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Volitionrx Limited  (NYSE: VNRX)

Volitionrx Limited's Quick Ratio

VNRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Volitionrx Limited's Cash & cash equivalent grew by % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Volitionrx Limited's Quick Ratio to 0.21, Quick Ratio remained below Volitionrx Limited average.

Within In Vitro & In Vivo Diagnostic Substances industry 12 other companies have achieved higher Quick Ratio than Volitionrx Limited in second quarter 2026. While total ranking remained the same in the Q2 2026 compared to the first quarter 2026 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents VNRX´s has?
What are VNRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VNRX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 46.01 % 63.99 % 56.99 % -62.28 % -70.17 %
Y / Y Cash & cash equivalent Change - - - - -
Quick Ratio MRQ 0.21 - - - -
VNRX's Total Ranking # # # # #
Seq. Current Liabilities Change -0.55 % 10.93 % 7.08 % 23.6 % 11.7 %
Seq. Cash & cash equivalent Change - - - - -



Quick Ratio second quarter 2026 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 13
Healthcare Sector # 819
Overall Market # 3356


Quick Ratio Statistics
High Average Low
11.78 3.5 0
(Mar 31 2016)   (Dec 31 2021)




Financial Statements
Volitionrx Limited's Current Liabilities $ 13 Millions Visit VNRX's Balance sheet
Volitionrx Limited's Cash & cash equivalent $ 3 Millions Visit VNRX's Balance sheet
Source of VNRX's Sales Visit VNRX's Sales by Geography


Cumulative Volitionrx Limited's Quick Ratio

VNRX's Quick Ratio for the trailling 12 Months

VNRX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -8.76 % -39.91 % -59.05 % -70.52 % -50.35 %
Y / Y Cash & cash equivalent TTM Growth - - - - -
Quick Ratio TTM 0.06 - - - -
Total Ranking TTM #
Seq. Current Liabilities TTM Growth 9.15 % 12.86 % 12.09 % -33.93 % -28.11 %
Seq. Cash & cash equivalent TTM Growth - - - - -

Quick ratio ranking by company, industry and sector >> Back to VNRX Financial Strength Comparisons >> Go to Compare VNRX Quick Ratio to its Competitors

On the trailing twelve months basis VNRX Cash & cash equivalent remained unchanged by % in Q2 2026 year on year, faster than Current Liabilities, this led to